1.79
-0.01
(-0.56%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 1.76 - 1.83 |
| 52 week | 1.49 - 6.33 |
| Open | 1.80 |
| Vol / Avg. | 605,243.00/1.01M |
| Mkt cap | 149.58M |
| P/E | - |
| Div/yield | - |
| EPS | -1.05 |
| Shares | 83.56M |
| Beta | 1.45 |
| Inst. own | 52% |
Events
Mar 26, 2013
ZIOPHARM ONCOLOGY INC to Discuss the PICASSO 3 trial - Conference Call
Mar 13, 2013
ZIOPHARM ONCOLOGY INC at Barclays Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -6399.50% | -12016.50% |
| Operating margin | -11791.50% | -12771.13% |
| EBITD margin | - | -12688.88% |
| Return on average assets | -69.96% | -100.39% |
| Return on average equity | -118.92% | -160.15% |
| Employees | 83 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 2020, 1180 Avenue of the Americas
NEW YORK, NY 10036
United States - Map
+1-646-2140700 (Phone)
+1-646-2140711 (Fax)
NEW YORK, NY 10036
United States - Map
+1-646-2140700 (Phone)
+1-646-2140711 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
ZIOPHARM Oncology, Inc. (ZIOPHARM) is a biopharmaceutical company that focuses on the discovery and development of new cancer therapies. ZIOPHARM is applying its technologies in cancer research to develop therapeutics for patients. The Company�s portfolio consists of five clinical-stage product candidates, as well as multiple research-stage candidates. ZIOPHARM�s clinical programs include palifosfamide (ZIO-201), IL-12 DNA, indibulin (ZIO-301) and darinaparsin (ZIO-101). Palifosfamide (ZIO-201) is a deoxyribonucleic acid (DNA)-targeted cancer treatment that bypasses drug resistance mediated by aldehyde dehydrogenase (ALDH), an enzyme associated with cancer stem cells, and has a favorable toxicity profile. IL-12 DNA is a DNA therapeutic that is delivered to the patient's tumor and expresses interleukin-12, a protein that controls anti-cancer immune responses.
Officers and directors
| Jonathan J. Lewis M.D., Ph.D. | Chief Executive Officer, Director | |
| Jason A. Amello | Chief Financial Officer, Executive Vice President | |
| Caesar J. Belbel | Executive Vice President, Chief Legal Officer, Secretary | |
| Murray Brennan M.D. | Non-Executive Lead Independent Director | |
| Randal J. Kirk | Director | |
| James A. Cannon | Independent Director | |
| Wyche Fowler Jr., J.D. | Independent Director | |
| Timothy McInerney | Independent Director |